Prescient gets FDA breakthrough status for colorectal cancer test

Prescient Metabiomics has received FDA breakthrough status for its non-invasive colorectal cancer test. The test, called LifeKit Prevent, identifies microbial DNA and RNA biomarkers associated with the new, abnormal growth of tissue in the gastrointestinal tract. By detecting these changes in the microbiome, Prescient says it can identify patients with precancerous polyps and early stage carcinomas, resulting in more people getting treated before the disease progresses.

Read More